What is claimed is:

1. A crystalline form of 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, 1-{4'-[3-methyl-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, or 1-{4'-[3-methyl-4-(1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, or a pharmaceutically acceptable salt, or solvate thereof.

2. The crystalline form of claim 1, wherein the pharmaceutically acceptable salt is a sodium salt, calcium salt, potassium salt, ammonium salt, L-arginine salt, L-lysine salt, or N-methyl-D-glucamine salt, or solvate thereof.

3. The crystalline form of claim 1, wherein the pharmaceutically acceptable salt is a sodium salt, or solvate thereof.

4. The crystalline form of claim 1 that is 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, or a pharmaceutically acceptable salt, or solvate thereof.

5. The crystalline form of claim 1 that is a pharmaceutically acceptable salt of 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, or solvate thereof.

6. The crystalline form of claim 1 ~~any one of claims 1-5~~, wherein the crystalline form is a hydrate.

7. The crystalline form of claim 1 that is 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, sodium salt.

8. The crystalline form of claim 2 that is a hydrate of 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, sodium salt.

9. The crystalline form of claim 8, wherein the crystalline form:

(a) has an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 13.2° 2-Theta, 17.2° 2-Theta, 19.3° 2-Theta, 22.4° 2-Theta, and 25.6° 2-Theta;

(b) has an X-ray powder diffraction (XRPD) pattern substantially the same as shown in **Figure 4**;

(c) has a DSC or a thermo-gravimetric analysis (TGA) substantially similar to the ones set forth in **Figure 5** and **Figure 6**;

(d) has an infrared spectrum substantially similar to the one set forth in **Figure 7**;

(e) was obtained from methyl ethyl ketone, acetonitrile, 1,4-dioxane/tert-butyl methyl ether, methyl ethyl ketone (MEK)/tert-butyl methyl, or ethanol/heptane;

(f) unit cell parameters substantially equal to the following at 25°C:

a(Å)	13.8714(2)
b(Å)	7.7379(2)
c(Å)	25.5253(5)
α °	90

Sol. Sites	-

or

(d) combinations thereof.

15. The crystalline form of claim 11, wherein the crystalline form is crystallized from ethanol, methanol, 2-methoxyethanol, ethanol, 1-propanol, 2-propanol, 1-butanol, butyl acetate, acetone, methylethyl ketone, anisole, toluene, nitromethane, acetonitrile, ethyl acetate, cumene, 1-4-dioxane, tetrahydrofuran, or combinations thereof.


16. A pharmaceutical composition comprising the crystalline form of any one of claim 1 ~~claims 1-15~~, or a pharmaceutically acceptable salt, or solvate thereof, and at least one inactive ingredient selected from pharmaceutically acceptable carriers, diluents and excipients.

17. The crystalline form of any one of claim 1 ~~claims 1-15~~ for use in medicine.

18. 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, 1-{4'-[3-methyl-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, or 1-{4'-[3-methyl-4-(1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, or a pharmaceutically acceptable salt, or solvate, or metabolite thereof, for use in medicine.

19. A process for the preparation of 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1) comprising Step (1) and Step (2):

(1) treatment of a compound of Formula XVIII with diphenylphosphoryl azide in the presence of (R)-(+)-1-phenylethanol:



XVIII

wherein,

R^1 is C_1-C_6alkyl;

to provide a compound of Formula X: